<DOC>
	<DOCNO>NCT00023829</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Androgens stimulate growth prostate cancer cell . Drugs , flutamide bicalutamide may stop adrenal gland produce androgen . Giving radiation therapy hormone therapy surgery remove tumor may kill tumor cell remain surgery effective treatment stage II stage III prostate cancer . It yet know radiation therapy combine hormone therapy effective either radiation therapy alone hormone therapy alone treat stage II stage III prostate cancer . ( Hormone therapy alone group close 12/9/2002 . ) PURPOSE : Randomized phase III trial compare effectiveness adjuvant radiation therapy plus hormone therapy radiation therapy alone hormone therapy alone treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival , disease-free survival , freedom distant metastasis , freedom PSA failure patient high-risk stage II III prostate cancer treat adjuvant set radiotherapy hormonal therapy v radiotherapy alone . - Compare qualitative quantitative toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord seminal vesicle invasion ( yes v ) , preoperative PSA ( 10 ng/mL less vs great 10 ng/mL ) , Gleason score ( 2-6 v 7 v 8-10 ) , positive surgical margin ( yes v ) , neoadjuvant hormonal therapy ( yes v ) . Patients randomize 1 3 treatment arm . ( Arm III close accrual 12/9/2002 . ) - Arm I : Patients undergo radiotherapy daily 5 day week 7 week . Beginning first day radiotherapy , patient also receive hormonal therapy comprise luteinizing-hormone-releasing hormone agonist every 1-4 month 2 year AND oral flutamide 3 time daily OR oral bicalutamide daily 1 month . - Arm II : Patients undergo radiotherapy arm I . - Arm III ( Closed accrual 12/9/2002 ) : Patients receive hormonal therapy arm I . Patients follow every 3 month 1 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 1,398 patient ( 699 per treatment arm ) accrue study within 5 year . ( Arm III close accrual 12/9/2002 . )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer T23 , N0 , M0 No metastatic disease Highrisk PSA relapse define Gleason score 7 high ≥ 1 follow OR Gleason score &lt; 7 ≥ 2 following : Preoperative PSA &gt; 10 ng/mL Positive surgical margin Seminal vesicle invasion Preoperative PSA ≤ 40.0 ng/mL Postoperative PSA ≤ 0.2 ng/mL Negative lymph node status lymph node sample dissection If lymph node status unknown , must &lt; 5 % risk involvement Roach formula PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : WBC ≥ 3,000/mm^3 Platelet count ≥ 130,000/mm^3 Hemoglobin ≥ 11.4 g/dL Hepatic : ALT ≤ 3 time normal Renal : Creatinine ≤ 2.5 mg/dL Other : No prior concurrent invasive malignancy within past 5 year except superficial nonmelanoma skin cancer No major medical psychiatric illness would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 5 year since prior chemotherapy Endocrine therapy : At least 60 day since prior finasteride At least 90 day since prior testosterone Prior pharmacologic androgen ablation prostate cancer allow initiate within past 10 month ( must switch study ablation therapy OR discontinue therapy randomize receive radiotherapy ) Radiotherapy : No prior radiotherapy pelvis No concurrent intensitymodulated radiotherapy Surgery : No prior orchiectomy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>